Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KMT2A rearrange |
| Therapy | Azacitidine + Revumenib + Venetoclax |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KMT2A rearrange | acute myeloid leukemia | sensitive | Azacitidine + Revumenib + Venetoclax | Phase I | Actionable | In a Phase I trial, combination of Vidaza (azacitidine), Veclexta (venetoclax), and Revuforj (revumenib) led to an overall response rate (ORR) of 88.4% (38/43), complete response (CR) rate of 67.4%, composite CR (CRc) rate of 81.4%, and median overall survival of 15.5 mo in older adults with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements (KMT2Ar) or NPM1 mutations, ORR, CR, and CRc rates were 100%, 78%, and 89% in KMT2Ar (n=9) (PMID: 40504618; NCT03013998). | 40504618 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40504618) | Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. | Full reference... |